CINGULATE INC. CING 深 沪
等待开盘 10-22 09:30:00 美东时间
3.85
+0.040
+1.05%
华盛通- 最 高3.90
- 今 开3.80
- 成交量 12.03万股
- 最 低 3.68
- 昨 收 3.81
- 总市值 2158.31万
- 52周最高 6.01
- 市盈率 静 --
- 换手率 2.15%
- 52周最低 3.02
- 委 比 73.95%
- 总股本 560.60万
- 历史最高 1236.00
- 量 比 0.31
- 振 幅 5.77%
- 历史最低 2.574
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10 to $17.
10-16 01:49
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 46.4% to $0.37 during Tuesday...
10-15 05:06
Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead ADHD Treatment Candidate For Children And Adults
Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
10-14 20:02
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Cingulate Inc. announced that the FDA has accepted the NDA for CTx-1301, a once-daily ADHD treatment leveraging its Precision Timed Release (PTR) technology for rapid onset and full-day coverage. Positive results from Phase 3 trials in adults and children support its efficacy and safety profile. The FDA has assigned a target action date of May 31, 2026. Cingulate is preparing for a potential launch in 2026.
10-14 12:00
Battery Tech Company Solidion Restructures $4M Financing to Boost Shareholder Value
Solidion Technology Inc. ("Solidion" or the "Company") (NASDAQ:STI), an advanced battery technology solutions provider, announces a comprehensive restructuring of its previous $4 million equity financing announced on
10-08 18:08
CONTANGO PROVIDES UPDATE ON FINANACING AND EXPLORATION PLANS
FAIRBANKS, Alaska, Sept. 26, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO), announces that it will hold a webinar on Friday, September 26, 2025 a...
09-26 22:07
Cingulate Inc Approves Stock Issuance Proposal
Cingulate Inc ( ($CING) ) has shared an update. On September 25, 2025, Cingulat...
09-26 05:30
CROWN HOLDINGS, INC. ANNOUNCES PRICING OF SENIOR NOTES
TAMPA, Fla., Sept. 22, 2025 /PRNewswire/ -- Crown Holdings, Inc. (NYSE: CCK) announced today that it has priced an offering of €500 million aggregate principal amount of 3.750% senior unsecu...
09-23 04:05
Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation
09-17 20:55
